SCHEMBL4287499

SCHEMBL4287499

CCOC(=O)CNC(=O)[C@@H](Cc1ccc(Cl)cc1Cl)NC(=O)OC(C)(C)C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.52
MAPT P10636 2/20 0.52
KDM4E B2RXH2 1/20 0.52
GAA P10253 1/20 0.52
PKM P14618 1/20 0.52
HPGD P15428 1/20 0.52
ALOX12 P18054 1/20 0.52
MC4R P32245 1/20 0.51
CTSL P07711 3/20 0.50
IDO1 P14902 2/20 0.47
CTSS P25774 11/20 0.45
CTSK P43235 10/20 0.45
CYP2C9 P11712 2/20 0.44
CYP3A4 P08684 1/20 0.44
TP53 P04637 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
CTSB P07858 2/20 0.43
CYP1A2 P05177 1/20 0.42
CYP2C19 P33261 1/20 0.42
HTT P42858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29780722 0.87 ALDH1A1 (0.63) ALDH1A1MAPTKDM4EGAAPKM
SCHEMBL1749008 0.81 MC4R (0.55) ALDH1A1MAPTKDM4EGAAPKM
SCHEMBL4288943 0.81 MC4R (0.55) ALDH1A1MAPTKDM4EGAAPKM
SCHEMBL1614505 0.81 MC4R (0.55) ALDH1A1MAPTKDM4EGAAPKM
SCHEMBL29726536 0.81 MC4R (0.55) ALDH1A1MAPTKDM4EGAAPKM
SCHEMBL29780799 0.80 MC4R (0.52) ALDH1A1MAPTKDM4EGAAPKM
SCHEMBL10944784 0.78 CTSS (0.69) CTSLCTSSCTSKCTSB
SCHEMBL10456411 0.78 CTSS (0.69) CTSLCTSSCTSKCTSB
SCHEMBL17348044 0.76 CTSD (0.57) ALDH1A1GAAMC4RCTSLTP53
SCHEMBL29780761 0.76 ALDH1A1 (0.49) ALDH1A1MAPTKDM4EGAAPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090227560-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-10 US disclosed
US-20090227560-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-10 US disclosed
US-20090227560-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-10 US disclosed
US-20090156612-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed
US-20090156612-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed
US-20090156612-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed
WO-2008139941-A1 SUBSTITUTED IMIDAZOLE COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156612-A1 Substituted imidazole compound and use thereof REN, ACE, AGT ALDH1A1 388/4885MAPT 3142/4885KDM4E 760/4885
US-20090227560-A1 Substituted imidazole compound and use thereof REN, ACE, AGT ALDH1A1 388/4885MAPT 3142/4885KDM4E 760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.